


**AMENDMENTS TO THE CLAIMS**

**In the Claims:**

1. (Currently Amended) A compound of formula (I)



(I)

or a salt, wherein:

n is an integer of from 2 to 8;

m is an integer of from 3 to 11, with the proviso that the sum of n + m is from 5 to 19;

R<sup>1</sup> is -XSO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>;

wherein X is -(CH<sub>2</sub>)<sub>p</sub>- or C<sub>2-6</sub> alkenylene;

p is an integer from 0 to 6;

R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, CONR<sup>8</sup>R<sup>9</sup>, phenyl and phenyl(C<sub>1-4</sub>alkyl)-,

or R<sup>6</sup> and R<sup>7</sup>, together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7- membered nitrogen – containing ring;

and R<sup>6</sup> and R<sup>7</sup> are each independently optionally substituted by 1 or 2 groups independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, hydroxy-substituted C<sub>1-6</sub>alkoxy,

C<sub>1-6</sub>haloalkyl, CO<sub>2</sub>R<sup>8</sup>, SO<sub>2</sub>R<sup>8</sup>R<sup>9</sup>, -CONR<sup>8</sup>R<sup>9</sup>, -NR<sup>8</sup>C(O)R<sup>9</sup> or a 5-, 6- or 7-membered heterocyclic ring;


R<sup>8</sup> and R<sup>9</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, phenyl and phenyl(C<sub>1-6</sub>alkyl)-;

R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halo, phenyl and C<sub>1-6</sub>haloalkyl;


R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen and C<sub>1-4</sub> alkyl with the proviso that the total number of carbon atoms in R<sup>4</sup> and R<sup>5</sup> is not more than 4,

and


Ar is a group selected from the group consisting of:



(a)




(b)



(c)

and



(d)

wherein R<sup>11</sup> represents hydrogen, halogen, -(CH<sub>2</sub>)<sub>q</sub>OR<sup>14</sup>, -NR<sup>14</sup>C(O)R<sup>15</sup>, -NR<sup>14</sup>SO<sub>2</sub>R<sup>15</sup>, -SO<sub>2</sub>NR<sup>14</sup>R<sup>15</sup>, -NR<sup>14</sup>R<sup>15</sup>, -OC(O)R<sup>16</sup> or OC(O)NR<sup>14</sup>R<sup>15</sup>, and R<sup>10</sup> represents hydrogen, halogen or C<sub>1-4</sub> alkyl;

or R<sup>11</sup> represents -NHR<sup>17</sup> and R<sup>10</sup> and -NHR<sup>17</sup> together form a 5- or 6-membered heterocyclic ring;

R<sup>12</sup> represents hydrogen, halogen, -OR<sup>14</sup> or -NR<sup>14</sup>R<sup>15</sup>, -OC(O)R<sup>16</sup> or -OC(O)NR<sup>14</sup>R<sup>15</sup>;

R<sup>13</sup> represents hydrogen, halogen, haloC<sub>1-4</sub> alkyl, -OR<sup>14</sup> or -NR<sup>14</sup>R<sup>15</sup>,

$R^{14}$  and  $R^{15}$  each independently represents hydrogen or  $C_{1-4}$  alkyl, or in the groups  
 $-NR^{14}R^{15}$ ,  $-SO_2NR^{14}R^{15}$  and  $-OC(O)NR^{14}R^{15}$ ,  $R^{14}$  and  $R^{15}$  independently represent hydrogen or  $C_{1-4}$  alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

$R^{16}$  represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen,  $C_{1-4}$  alkyl, hydroxy,  $C_{1-4}$  alkoxy or halo  $C_{1-4}$  alkyl; and

$q$  is zero or an integer from 1 to 4;

provided that Ar is not a group (a) wherein

$R^{11}$  is  $(CH_2)_qOR^{14}$  or  $NR^{14}COR^{15}$ , and  $R^{12}$  is  $OR^{14}$ .

2. (Previously Presented) A compound of formula (I) according to claim 1 wherein, in the group Ar,  $R^{11}$  represents halogen,  $-(CH_2)_qOR^{14}$ ,  $-NR^{14}C(O)R^{15}$ ,  $-NR^{14}SO_2R^{15}$ ,  $-SO_2NR^{14}R^{15}$ ,  $-NR^{14}R^{15}$ ,  $-OC(O)R^{16}$  or  $OC(O)NR^{14}R^{15}$ ,

and  $R^{10}$  represents hydrogen,

or  $R^{11}$  represents  $-NHR^{17}$  and  $R^{10}$  and  $-NHR^{17}$  together form a 5- or 6-membered heterocyclic ring;

and

$R^{13}$  represents hydrogen, halogen, halo,  $C_{1-4}$  alkyl,  $-OR^{14}$ , or  $-NR^{14}R^{15}$ ;

3. (Previously Presented) A compound of formula (I) according to claim 1 wherein the group R<sup>1</sup> is attached to the meta-position relative to the –O–(CH<sub>2</sub>)<sub>m</sub> link.


4. (Previously Presented) A compound of formula (I) according to claim 1 wherein R<sup>1</sup> represents SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> wherein R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen and C<sub>1-6</sub>alkyl.

5. (Previously Presented) A compound of formula (I) according to claim 1 wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen and methyl.


6. (Previously Presented) A compound of formula (I) according to claim 1 wherein R<sup>2</sup> and R<sup>3</sup> each represent hydrogen.

7. (Previously Presented) A compound of formula (I) according to claim 1 wherein n is 5 or 6 and m is 3 or 4 such that m + n is 8, 9 or 10.


8. (Previously Presented) A compound of formula (I) according to claim 1 wherein Ar represents a group selected from the group consisting of:




(i)




(ii)




(iii)




(viii)




(ix)




(x)




(xi)




(iv)




(v)




(vi)




(vii)




(xv)




(xvi)




(xvii)




(xviii)



(xix)



(xx)



(xiv)

9. (Canceled)

10. (Previously Presented) A compound of formula (I) according to claim 8 wherein R<sup>1</sup> is XSO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and Ar is selected from the group consisting of (iii), (iv), (xiv), (xv), (xvi) and (xix).

11. (Previously Presented) A compound selected from the group consisting of:

8-Hydroxy-5-((1*R*)-1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)quinolin-2(1*H*)-one;

3-{4-[(6-[(2*R*)-2-Hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}hexyl]oxy}butyl]benzenesulfonamide;

5-Hydroxy-8-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2*H*-1,4-benzoxazin-3(4*H*)-one;

3-{4-[(6-[(2-hydroxy-2-(5-hydroxy-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-8-yl)ethyl]amino}hexyl]oxy}butyl]benzenesulfonamide;

4-Hydroxy-7-((1*R*)-1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-1,3-benzothiazol-2(3*H*)-one;

4-Hydroxy-7-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-1,3-benzothiazol-2(3*H*)-one;

3-{4-[(6-[(2*R*)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]amino}hexyl]oxy}butyl]benzenesulfonamide;

3-(4-[(6-[(2-Hydroxy-2-[5-hydroxy-6-(hydroxymethyl)pyridin-2-yl]ethyl]amino)hexyl]oxy}butyl]benzenesulfonamide;

3-[4-((6-[(2*R*)-2-Hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl]amino)hexyl]oxy}butyl]benzenesulfonamide;

3-[3-[(7-[(2*R*)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]amino)heptyl]oxy]propyl]benzenesulfonamide;

3-(3-[(7-[(2-Hydroxy-2-[5-hydroxy-6-(hydroxymethyl)pyridin-2-yl]ethyl]amino)heptyl]oxy)propyl]benzenesulfonamide;

3-[3-((7-[(2*R*)-2-Hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl]amino)heptyl]oxy)propyl]benzenesulfonamide;

3-{3-[(7-[(2*R*)-2-Hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino)heptyl]oxy}propyl]benzenesulfonamide;

3-(3-[(7-[(2*R*)-2-[3-(Formylamino)-4-hydroxyphenyl]-2-hydroxyethyl]amino)heptyl]oxy)propyl]benzenesulfonamide;

and a salt thereof.


12-13. (Canceled)

14. (Previously Presented) A pharmaceutical formulation comprising a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

15. (Canceled)

16. (Previously Presented) A process for the preparation of a compound of formula (I), according to claim 1, or a salt thereof, which comprises:

deprotecting a protected intermediate of formula (II):



or a salt or solvate thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, m and n are as defined for the compounds of formula (I) R<sup>25</sup> represents an optionally protected form of Ar, and R<sup>26</sup> and R<sup>27</sup> each independently represent either hydrogen or a protecting group, provided that the compound of formula (II) contains at least one protecting group,

wherein said process may further optionally comprise one or more of the following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt, or
- (iv) converting a group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup> to another group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup>.

17. (Previously Presented) A compound of the formula (I) according to claim 1, wherein m is an integer ranging from 3 to 7.


18. (Previously Presented) A compound of the formula (I) according to claim 1, wherein the sum of n + m ranges from 5 to 12.

19. (Previously Presented) A compound of the formula (I) according to claim 1, wherein p is an integer ranging from 0 to 4.


20-22. (Canceled)

23. (Previously Presented) A process for the preparation of a compound of formula (I), according to claim 1 or a salt thereof, which comprises:

reacting a compound of formula (XIII):



Wherein Ar is as defined above with a compound of formula (VI):



wherein L is a leaving group and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, n and m are as defined for compounds of formula (I);

wherein said process may further optionally comprise one or more of following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt, or
- (iv) converting a group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup> to another group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup>.

24. (Previously Presented) A process according to claim 23, wherein the leaving group comprises a halo group.

25. (Previously Presented) A process according to claim 24, wherein the halo group is selected from the group consisting of chloro, bromo, and iodo.

26. (Previously Presented) A process according to claim 23, wherein the leaving group comprises a sulphonate group.


27. (Previously Presented) A process according to claim 26, wherein the sulphonate group is a methanesulphonate group.

28. (Previously Presented) A process for the preparation of a compound of formula (I), according to claim 1, or a salt thereof, which comprises:

reacting a compound of formula (XV):



wherein L is a leaving group, with an amine of formula (XVI):



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, n and m are as defined for formula (I); and wherein said process may further optionally comprise one or more of the following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt or

(iv) converting a group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup> to another group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup>.

29. (Previously Presented) A process according to claim 28, wherein the leaving group comprises a halo group.


30. (Previously Presented) A process according to claim 28, wherein the halo group is selected from the group consisting of chloro, bromo, and iodo.

31. (Previously Presented) A process according to claim 28, wherein the leaving group comprises a sulphonate group.

32. (Previously Presented) A process according to claim 28, wherein the sulphonate group is a methanesulphonate group.


33. (Previously Presented) A process for the preparation of a compound of formula (I), according to claim 1 or a salt thereof, wherein said process is selected from the group consisting of (i) and (ii):

(i) reacting a compound of formula (XIII):




Wherein Ar is as hereinbefore defined and R<sup>34</sup> is a chiral auxiliary group,

with a compound of formula (XVII):




wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, n and m are as hereinbefore defined;  
optionally followed by removing said chiral auxiliary group R<sup>34</sup>;

and (ii) reacting a compound of formula (XVIII):



wherein Ar is as hereinbefore defined; with an amine of formula (XVI):



under conditions suitable to effect reductive amination,

wherein said process may further optionally comprise one or more of the following steps in any order:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting the product to a corresponding salt,
- (iv) converting a group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup> to another group R<sup>1</sup>, R<sup>2</sup> and/or R<sup>3</sup>.